London-based neurological HealthTech startup CoMind, a developer of non-invasive brain monitors, has raised €51 million in its latest funding round, bringing its total funding to €85 million, led by Plural.
- Established in 2018 by James Dacombe, CoMind develops non-invasive brain monitoring systems for clinical use. Its primary product, CoMind One, uses advanced infrared light technology to measure key neurophysiological parameters, cerebral perfusion, cerebral autoregulation, and intracranial pressure, without requiring invasive procedures.
- The system employs a small adhesive sensor placed on the patient’s forehead, transmitting real-time physiological data to a dedicated display or integrating with existing multiparameter monitors.
- The technology is designed for use in critical care settings, including intensive care units, cardiac and vascular surgery, and management of traumatic brain injury, providing clinicians with continuous, multidimensional insight into brain function that is not accessible through conventional non-invasive methods.
Details of the deal
- The funidng round also saw participation from LocalGlobe, Latitude, Octopus Ventures, Crane Venture Partners, Angelini Ventures, and Lord David Prior.
“James is truly a generational Founder and partnering with him and his team has been one of our great privileges as investors. We couldn’t be more excited to continue supporting them as they redefine how the brain is measured, and, ultimately, how it’s treated,” explains Julia Hawkins, General Partner at LocalGlobe and Latitude.
- CoMind will use the capital raised to advance its clinical and regulatory efforts in the United States, including conducting additional trials needed for FDA approval.
- The investment will also support scaling manufacturing capabilities, expanding the team across engineering, clinical, and regulatory functions, and strengthening collaborations with medical device partners to prepare for broader adoption of CoMind One in neurocritical care settings.
